Navidea Biopharmaceuticals to Present at Upcoming Investor Conferences
– Navidea Executives to Provide Business and Development Program Updates –
DUBLIN, Ohio--(BUSINESS WIRE)-- Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that management will meet with investors and make presentations at the Rodman & Renshaw Annual Global Investment Conference, at the ThinkEquity 9th Annual Growth Conference and at the Burrill Personalized Medicine Meeting. Investors and the public are invited to listen to live webcasts of the presentations listed below. Following the conference, these webcasts will be archived for approximately 30 days.
Dr. Mark Pykett, Navidea President and CEO, will present at 11:15 AM ET, Tuesday, September 11, 2012, at the Rodman & Renshaw Annual Global Investment Conference being held at the Waldorf-Astoria in New York City. The link to the webcast is: http://wsw.com/webcast/rrshq22/navb.
Brent Larson, Navidea Senior Vice President and CFO will present at 4:30 PM ET on Wednesday, September 12, 2012, at the ThinkEquity 9th Annual Growth Conference at the Le Parker Meridien in New York City. The link to the webcast is: http://wsw.com/webcast/tep22/navb/.
Dr. Thom Tulip, Executive Vice President and Chief Business Officer, will provide a company update at the Burrill Personalized Medicine Meeting at The Bently Reserve in San Francisco, CA on Thursday, September 13, 2012, from 12:30-2:00 PM PDT. Dr. Tulip will also participate in a panel discussion, “Transforming Educated Guesses to Tailor Made Treatments - Bringing Together the Players” on September 13, 2012 from 4:30-5:30 PM PDT. The Burrill Conference is not being webcast.
About Navidea
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) is a biopharmaceutical company focused on the development and commercialization of precision diagnostics and radiopharmaceutical agents. Navidea is actively developing four radiopharmaceutical agent platforms – Lymphoseek®, NAV4694, E-IACFT and RIGScanTM – to help identify the presence and status of undetected disease and enable better diagnostic accuracy, clinical decision-making and ultimately patient care. Navidea’s strategy is to deliver superior growth and shareholder return by bringing to market novel radiopharmaceutical agents and advancing the Company’s pipeline through selective acquisitions, global partnering and commercialization efforts. For more information, please visit www.navidea.com.
Navidea Biopharmaceuticals
Brent Larson, 614-822-2330
Sr.
VP & CFO
Source: Navidea Biopharmaceuticals, Inc.
Released September 5, 2012